Holen Sie sich die Stockscreener-App
27.00
0.86%
0.245
Schlusskurs vom Vortag:
$26.76
Offen:
$26.76
24-Stunden-Volumen:
1.35M
Relative Volume:
0.70
Marktkapitalisierung:
$4.57B
Einnahmen:
$890.53M
Nettoeinkommen (Verlust:
$30.57M
KGV:
150.03
EPS:
0.18
Netto-Cashflow:
$80.53M
1W Leistung:
+6.13%
1M Leistung:
+19.58%
6M Leistung:
+21.03%
1J Leistung:
+43.87%
1-Tages-Spanne:
$26.70
$27.66
1-Wochen-Bereich:
$25.29
$27.73
52-Wochen-Spanne:
$13.40
$27.73
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Firmenname
Acadia Pharmaceuticals Inc
Sektor
Branche
Telefon
858-558-2871
Adresse
12830 EL CAMINO REAL, SAN DIEGO
Vergleichen Sie ACAD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
26.98 | 4.53B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.32 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.88 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
892.74 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.73 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-05-21 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2025-01-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-03-12 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-12 | Bestätigt | Needham | Buy |
| 2024-01-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-01-24 | Hochstufung | Needham | Hold → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Eingeleitet | Citigroup | Buy |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-11-06 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-17 | Eingeleitet | UBS | Buy |
| 2023-10-10 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-11-01 | Eingeleitet | Loop Capital | Hold |
| 2022-08-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-21 | Herabstufung | Jefferies | Buy → Underperform |
| 2022-06-16 | Hochstufung | Jefferies | Hold → Buy |
| 2022-03-16 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-12-21 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-06-10 | Eingeleitet | Berenberg | Hold |
| 2021-04-07 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-04-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-04-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2021-03-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Herabstufung | Stifel | Buy → Hold |
| 2020-12-16 | Eingeleitet | Mizuho | Buy |
| 2020-11-16 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-07 | Hochstufung | Stifel | Hold → Buy |
| 2020-04-16 | Eingeleitet | Jefferies | Buy |
| 2020-03-31 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2019-12-16 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Eingeleitet | Oppenheimer | Perform |
| 2019-10-01 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-09-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Bestätigt | Needham | Buy |
| 2018-12-10 | Eingeleitet | Canaccord Genuity | Hold |
| 2018-09-21 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Bestätigt | Stifel | Hold |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-08-06 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
Norges Bank Invests $31.68 Million in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
(ACAD) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Marshall Wace LLP Purchases 1,639,315 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Swing Trade: Can ACADIA Pharmaceuticals Inc stock maintain growth trajectoryJuly 2025 Short Interest & Verified Stock Trade Ideas - BỘ NỘI VỤ
Assessing ACADIA Pharmaceuticals Valuation After Strong 2024 Share Price Rally - Yahoo Finance
MACD Signal: Is ACADIA Pharmaceuticals Inc stock a buy in volatile marketsJuly 2025 Market Mood & Community Consensus Trade Signals - BỘ NỘI VỤ
ACADIA Pharmaceuticals (ACAD) Is Up 9.6% After Earnings Beat And NUPLAZID Patent Extension News - Yahoo Finance
Assessing Acadia Pharmaceuticals (ACAD) Valuation After Strong Q3 Results and Extended NUPLAZID Patent Protection - Yahoo Finance
State Board of Administration of Florida Retirement System Increases Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (ACAD) Receives a Buy from UBS - The Globe and Mail
ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 12-Month HighShould You Buy? - MarketBeat
Is ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Recent Stock Performance Tethered To Its Strong Fundamentals? - 富途牛牛
Stonepine Capital Management LLC Has $4.85 Million Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals stock hits 52-week high at 26.65 USD By Investing.com - Investing.com Nigeria
Fisher Asset Management LLC Sells 44,710 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Edgestream Partners L.P. Sells 47,964 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Is ACADIA Pharmaceuticals Inc. stock safe for conservative investorsQuarterly Performance Summary & Weekly High Return Stock Opportunities - Newser
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality (ACAD) - Seeking Alpha
Acadia Pharmaceuticals stock hits 52-week high at 26.65 USD - Investing.com India
UBS Adjusts ACADIA Pharmaceuticals Price Target to $35 From $39, Maintains Buy Rating - marketscreener.com
Acadia Pharmaceuticals stock price target lowered to $35 at UBS By Investing.com - Investing.com UK
Can ACADIA Pharmaceuticals Inc. stock maintain operating margins2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - Newser
ACADIA Pharmaceuticals Earnings Notes - Trefis
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? - The Motley Fool
Acadia to pivot to Alzheimer’s psychosis pipeline, accd to Wall Street analysts - Yahoo Finance UK
Capital Fund Management S.A. Reduces Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
How ACADIA Pharmaceuticals Inc. stock benefits from tech adoption2025 Trading Volume Trends & AI Driven Stock Price Forecasts - Newser
ACADIA Pharmaceuticals (ACAD) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Mizuho Maintains 'Neutral' Rating on ACAD, Raises Price Target t - GuruFocus
Acadia Pharmaceuticals stock price target raised by Mizuho to $29 - Investing.com Canada
ACADIA Pharmaceuticals Inc Stock Analysis and ForecastCurrency Fluctuation Impact & Free Trading Psychology Sessions - earlytimes.in
F m Investments LLC Lowers Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Ensign Peak Advisors Inc Cuts Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
American Century Companies Inc. Sells 65,361 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Is ACADIA Pharmaceuticals Inc a good long term investmentEvening Star Patterns & High Profit Growth Stocks - earlytimes.in
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock - MSN
Summit Global Investments Reduces Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Prudential Financial Inc. Raises Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
(ACAD) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Stocks Flashing Renewed Technical Strength: ACADIA Pharmaceuticals - Investor's Business Daily
Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study - Springer
Geode Capital Management LLC Buys 69,584 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
LSV Asset Management Increases Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. (ACAD) Options Chain - Yahoo! Finance Canada
Acadia Pharmaceuticals Reports Strong Q3 2025 Growth - MSN
How ACADIA Pharmaceuticals Inc. stock trades before earningsInsider Buying & Real-Time Market Trend Scan - newser.com
Acadia Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference - BioSpace
Is ACADIA Pharmaceuticals Inc. stock oversold or undervalued2025 Growth vs Value & AI Based Buy/Sell Signal Reports - newser.com
Mark Schneyer Sells 10,262 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Finanzdaten der Acadia Pharmaceuticals Inc-Aktie (ACAD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):